explore -WSS

explore

author：knowledge 2025-09-29 19:59:46 - browse：396

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

WSS

The nurse manager staffing crisis is hurting patients

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

How to save health care price transparency rules

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Readout LOUD podcast: live from JPM 2024

Boston's new lab space is opening empty

knowledge

explore

leisure time

Supreme Court strikes down use of affirmative action

Male and female sex labels in research insufficient, scientists say

Medical leaders decry Supreme Court decision on affirmative action

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Hollywood unions extend contract negotiations for actors

New Medicare drug pricing powers could soon be upended in court

The cancer drug shortage isn’t new — and neither are the solutions

Designating disabled people as health disparity population is crucial

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

focus

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Readout Newsletter: CAR

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

John Green on his newest strategy for fighting tuberculosis

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

focus

hotspot

hotspot